Axs Investments LLC Incyte Corp Transaction History

Axs Investments LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Aug 16, 2024	BUY	$56.55 - $66.59 $309,328 - $364,247	5,470 New	5,470 $311,000
Q1 2024 May 13, 2024	BUY	$56.55 - $66.59 $44,109 - $51,940	780 Added 16.63%	5,470 $311,000
Q4 2023 Feb 09, 2024	BUY	$52.16 - $64.19 $35,208 - $43,328	675 Added 16.81%	4,690 $294,000
Q3 2023 Nov 09, 2023	BUY	$57.77 - $65.93 $73,945 - $84,390	1,280 Added 46.8%	4,015 $231,000
Q2 2023 Aug 10, 2023	BUY	$60.95 - $75.51 $29,499 - $36,546	484 Added 21.5%	2,735 $170,000
Q1 2023 May 12, 2023	BUY	$70.23 - $86.01 $56,464 - $69,152	804 Added 55.56%	2,251 $162,000
Q4 2022 Feb 13, 2023	BUY	$67.18 - $84.11 $97,209 - $121,707	1,447 New	1,447 $116,000

697

188M

585K

410K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Axs Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Axs Investments LLC with notifications on news.